Morgan Stanley Chemomab Therapeutics Ltd. Transaction History

Morgan Stanley

$1.27 Trillion
Q2 2024

A detailed history of Morgan Stanley transactions in Chemomab Therapeutics Ltd. stock. As of the latest transaction made, Morgan Stanley holds 7,200 shares of CMMB stock, worth $11,088. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,200

Previous 2,797 157.42%

Holding current value

$11,088

Previous $2,000 200.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.59 - $1.29 $2,597 - $5,679	4,403 Added 157.42%	7,200 $6,000
Q1 2024 Aug 16, 2024	SELL	$0.5 - $0.86 $34,059 - $58,581	-68,118 Reduced 96.06%	2,797 $2,000
Q1 2024 May 15, 2024	SELL	$0.5 - $0.86 $34,059 - $58,581	-68,118 Reduced 96.06%	2,797 $2,000
Q4 2023 Aug 16, 2024	BUY	$0.45 - $0.9 $28,671 - $57,343	63,715 Added 884.93%	70,915 $36,000
Q4 2023 Feb 13, 2024	BUY	$0.45 - $0.9 $31,911 - $63,823	70,915 New	70,915 $36,000
Q2 2023 Aug 14, 2023	SELL	$1.0 - $1.84 $7,700 - $14,168	-7,700 Reduced 98.72%	100 $0
Q1 2023 May 15, 2023	BUY	$1.44 - $2.94 $1,728 - $3,528	1,200 Added 18.18%	7,800 $12,000
Q4 2022 Feb 14, 2023	BUY	$1.9 - $3.2 $760 - $1,280	400 Added 6.45%	6,600 $21,000
Q3 2022 Nov 14, 2022	BUY	$2.33 - $4.0 $1,409 - $2,420	605 Added 10.81%	6,200 $15,000
Q2 2022 Aug 15, 2022	BUY	$2.58 - $4.88 $14,435 - $27,303	5,595 New	5,595 $21,000
Q1 2022 May 13, 2022	SELL	$3.53 - $7.2 $41,099 - $83,829	-11,643 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$6.41 - $11.13 $74,022 - $128,529	11,548 Added 12155.79%	11,643 $80,000
Q3 2021 Nov 15, 2021	BUY	$11.08 - $19.17 $1,052 - $1,821	95 New	95 $1,000

Others Institutions Holding CMMB

# of Institutions

Shares Held

2.68M

Call Options Held

Put Options Held

View Full List

About Chemomab Therapeutics Ltd.

Ticker CMMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,431,700
Market Cap $17.6M
Description
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (...

More about CMMB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account